PHBID (Neorich Biopharma Tech Co) Other Stockholders Equity: $-0.00 Mil (As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Neorich Biopharma Tech Co Other Stockholders Equity?

Neorich Biopharma Tech Co PHBID -44.44% Other Stockholders Equity is $-0.00 Mil as of Jun. 2023.

Neorich Biopharma Tech Co's Other Stockholders Equity for the quarter that ended in Jun. 2023 was $-0.00 Mil.

Neorich Biopharma Tech Co's quarterly Other Stockholders Equity increased from Dec. 2022 ($-0.00 Mil) to Mar. 2023 ($-0.00 Mil) but then declined from Mar. 2023 ($-0.00 Mil) to Jun. 2023 ($-0.00 Mil).

Neorich Biopharma Tech Co's annual Other Stockholders Equity declined from Sep. 2020 ($0.18 Mil) to Sep. 2021 ($-0.00 Mil) but then increased from Sep. 2021 ($-0.00 Mil) to Sep. 2022 ($0.00 Mil).

Neorich Biopharma Tech Co Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Neorich Biopharma Tech Co's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neorich Biopharma Tech Co Other Stockholders Equity Chart

Neorich Biopharma Tech Co Annual Data
Trend Apr08 Apr09 Sep18 Sep19 Sep20 Sep21 Sep22
Other Stockholders Equity
Get a 7-Day Free Trial 0.00 -0.00 0.18 -0.00 0.00

Neorich Biopharma Tech Co Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.00 -0.00 -0.00 -0.00

Neorich Biopharma Tech Co Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $-0.00 Mil mean?
Neorich Biopharma Tech Co (PHBID) has a Other Stockholders Equity of $-0.00 Mil as of Jun. 2023. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Neorich Biopharma Tech Co and its competitors.
Is Neorich Biopharma Tech Co's Other Stockholders Equity too high?
Neorich Biopharma Tech Co's current Other Stockholders Equity is $-0.00 Mil.
How does Neorich Biopharma Tech Co's Other Stockholders Equity compare to DVLP and CSTF?
Neorich Biopharma Tech Co's Other Stockholders Equity of $-0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Neorich Biopharma Tech Co and its competitors. Neorich Biopharma Tech Co's current Other Stockholders Equity is $-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neorich Biopharma Tech Co stock overvalued right now?
Neorich Biopharma Tech Co (PHBID) has a current Other Stockholders Equity of $-0.00 Mil. The current Other Stockholders Equity is $-0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Neorich Biopharma Tech Co (PHBID), the current Other Stockholders Equity is $-0.00 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neorich Biopharma Tech Co Business Description

Address 112 North Curry Street, Carson, NV, USA, 89703
Pharmagreen Biotech Inc is a biotech science company with specialized products and services in the cannabis industry. The company plans to produce and sell tissue culture plantlets and cannabis oil. Its line of nutraceutical products is a proprietary blend of therapeutic plants and mushrooms. It is developing its business model beyond just cannabis, and is focused on near term revenues from its proprietary blend of therapeutic plants and fungi, a nutraceutical wellness product. Utilizing the Company's expertise in plant genetics, Its transgenic program uses the newest technology available to research and create nutraceuticals, protein-based vaccines, and daily supplements with the potential to improve lives and address a wide variety of disease conditions.